AVITA Medical, Inc.
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AVITA Medical, Inc. | |
| (Registrant) | |
| Date: February 12, 2026 | /s/ Cary Vance |
|---|---|
| Cary Vance | |
| Interim Chief Executive Officer (Principal Executive Officer) | |
| Date: February 12, 2026 | /s/ David O’Toole |
| David O’Toole | |
| Chief Financial Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Cary Vance | Interim Chief Executive Officer and Chairman of the Board of Directors | February 12, 2026 |
| Cary Vance | (Principal Executive Officer) | |
| /s/ David O’Toole | Chief Financial Officer | February 12, 2026 |
| David O’Toole | (Principal Financial and Accounting Officer) | |
| /s/ Jan Stern Reed | Lead Independent Director | February 12, 2026 |
| Jan Stern Reed | ||
| /s/ Jeremy Curnock Cook | Director | February 12, 2026 |
| Jeremy Curnock Cook | ||
| /s/ Professor Suzanne Crowe | Director | February 12, 2026 |
| Suzanne Crowe | ||
| /s/ Robert McNamara | Director | February 12, 2026 |
| Robert McNamara | ||
| /s/ Dr. Michael Tarnoff | Director | February 12, 2026 |
| Michael Tarnoff | ||
| /s/ Joe Woody | Director | February 12, 2026 |
| Joe Woody | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | ||
| Report of Independent Registered Public Accounting Firm | (PCAOB ID Number 248) | F-2 |
|---|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-3 | |
| Consolidated Statements of Operations for the Years-Ended December 31, 2025 and 2024 | F-4 | |
| Consolidated Statements of Comprehensive Loss for the Years-Ended December 31, 2025 and 2024 | F-5 | |
| Consolidated Statements of Stockholders’ Equity for the Years-Ended December 31, 2025 and 2024 | F-6 | |
| Consolidated Statements of Cash Flows for the Years-Ended December 31, 2025 and 2024 | F-7 | |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.